These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 23048110)

  • 1. Secondary patenting of branded pharmaceuticals: a case study of how patents on two HIV drugs could be extended for decades.
    Amin T; Kesselheim AS
    Health Aff (Millwood); 2012 Oct; 31(10):2286-94. PubMed ID: 23048110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentration.
    Bierman WF; van Vonderen MG; Veldkamp AI; Burger DM; Danner SA; Reiss P; van Agtmael MA
    Antivir Ther; 2011; 16(5):647-55. PubMed ID: 21817186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals.
    van der Lugt J; Lange J; Avihingsanon A; Ananworanich J; Sealoo S; Burger D; Gorowara M; Phanuphak P; Ruxrungtham K
    Antivir Ther; 2009; 14(7):1001-4. PubMed ID: 19918104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
    Ghosn J; Flandre P; Cohen-Codar I; Girard PM; Chaix ML; Raffi F; Dellamonica P; Ngovan P; Norton M; Delfraissy JF;
    HIV Med; 2010 Feb; 11(2):137-42. PubMed ID: 19682100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Method for Approximating Future Entry of Generic Drugs.
    Beall RF; Darrow JJ; Kesselheim AS
    Value Health; 2018 Dec; 21(12):1382-1389. PubMed ID: 30502781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lopinavir/ritonavir. (Kaletra).
    Res Initiat Treat Action; 2000 Dec; 6(4):16-8. PubMed ID: 11708169
    [No Abstract]   [Full Text] [Related]  

  • 7. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.
    Pulido F; Arribas JR; Delgado R; Cabrero E; González-García J; Pérez-Elias MJ; Arranz A; Portilla J; Pasquau J; Iribarren JA; Rubio R; Norton M;
    AIDS; 2008 Jan; 22(2):F1-9. PubMed ID: 18097218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ART regimen protects children from malaria.
    BMJ; 2012 Dec; 345():e8214. PubMed ID: 23207506
    [No Abstract]   [Full Text] [Related]  

  • 9. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
    Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
    J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy.
    Calza L; Manfredi R; Trapani F; Salvadori C; Colangeli V; Borderi M; Grossi G; Motta R; Viale P
    Scand J Infect Dis; 2012 May; 44(5):381-7. PubMed ID: 22263609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NIH denies march-in rights on Norvir patent.
    Harrison C
    Nat Rev Drug Discov; 2013 Dec; 12(12):898. PubMed ID: 24287772
    [No Abstract]   [Full Text] [Related]  

  • 13. Ownership of knowledge--the role of patents in pharmaceutical R&D.
    Correa CM
    Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-HIV agents. Lopinavir and ritonavir (Kaletra) tablets get tested.
    TreatmentUpdate; 2008 Mar; 20(2):5-6. PubMed ID: 18661644
    [No Abstract]   [Full Text] [Related]  

  • 15. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
    Raguin G; Chêne G; Morand-Joubert L; Taburet AM; Droz C; Le Tiec C; Clavel F; Girard PM;
    Antivir Ther; 2004 Aug; 9(4):615-25. PubMed ID: 15456093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.
    Naeger LK; Struble KA
    AIDS; 2006 Apr; 20(6):847-53. PubMed ID: 16549968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
    Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
    Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Legitimate patent extension or patent system abuse?
    Atkinson JD; Moodie RS
    Pharm Pat Anal; 2013 May; 2(3):317-24. PubMed ID: 24237059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategic options for brand-name prescription drugs when patents expire.
    Mehta SC; Mehta SS
    Health Mark Q; 1997; 14(3):107-14. PubMed ID: 10167309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.